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background: Oxidative stress is considered to be involved in the establishment and development of endometriosis. Thioredoxin
(TRX) is an endogenous redox regulator that protects cells against oxidative stress, and TRX-binding protein-2 (TBP-2) is a negative regulator
of TRX in the biological function and expression. The aim of this study was to investigate the roles of TRX and TBP-2 in the pathophysiology
of endometriosis.
methods: A total of 35 patients with histologically conﬁrmed endometriosis and 31 patients without endometriosis participated in this
study. Real-time polymerase chain reaction was used to quantify TRX and TBP-2 mRNA levels, and immunohistochemistry (IHC) was used
to assess TRX and TBP-2 protein localization in the endometrium. Serum and peritoneal ﬂuid levels of TRX and TBP-2 were measured using
a speciﬁc commercial ELISA.
results: There were no signiﬁcant differences in TRX mRNA levels in the endometrium of patients with endometriosis and the control
groups. However, TBP-2 mRNA levels in the endometrium were lower, and the TRX to TBP-2 ratio was higher in patients with endome-
triosis than in the control group. In particular, the TRX to TBP-2 ratio was signiﬁcantly higher during late secretory and menstrual phase in
patients with endometriosis compared with the control group. IHC studies also showed the decreased TBP-2 immunoreactivity in patients
with endometriosis compared with the control group. There was no correlation between TRX and TBP-2 mRNA levels in patients with
endometriosis, whereas TRX mRNA levels were positively correlated with TBP-2 mRNA levels in the control group. There were no signiﬁ-
cant differences between the two groups in TRX and TBP-2 levels in serum or peritoneal ﬂuid.
conclusions: Aberrant expression of TRX and TBP-2 in the endometrium may be associated with the establishment of endometriosis.
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Introduction
Endometriosis, or the growth of hormone-responsive endometrial glands
and stroma outside of the uterus, is a chronic pleomorphic condition
responsible for infertility and pelvic pain. It is a common disease, reported
to occur in around 10% of women of reproductive age and in 30–50% of
infertile women (Cramer and Missmer, 2002; Pritts and Taylor, 2003).
Various theories have been proposed to explain the pathogenesis of
endometriosis, but its overall etiology has not yet been established.
Oxidative stress is associated with numerous pathological con-
ditions including aging, cardiovascular disease, neurodegenerative
disease, and cancer. Oxidative stress is also considered to be one
of the most important factors affecting the establishment and
development of endometriosis (Jackson et al., 2005; Agarwal et al.,
2006). Many previous studies have reported that levels of some oxi-
dative stress and antioxidant biomarkers found in serum or peritoneal
ﬂuid are signiﬁcantly different between patients with and without
endometriosis (Ho et al., 1997; Jackson et al., 2005; Verit et al.,
2008; Lambrinoudaki et al., 2009). Additionally, it has been reported
that there is no cyclic variation of antioxidant enzymes in the endome-
trium of patients with endometriosis (Ota et al., 1999). However,
these studies varied in their method, and their results are not consist-
ent. Therefore, the association between oxidative stress and endome-
triosis is still a matter of debate.
Thioredoxin (TRX) is a redox-regulating antioxidant protein that
prevents cell damage from oxidative stress (Nordberg and Arner,
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2001). TRX exhibits various biological activities in cellular processes
such as cell proliferation and apoptosis. TRX also controls many tran-
scription factors such as AP-1 (Abate et al., 1990), NF-kB (Qin et al.,
1994) and p53 (Ueno et al., 1999). TRX is linked to increased tumor
cell growth and inhibited apoptosis and has been reported to be
associated with various human cancers (Kaimul et al., 2007). In
addition, TRX has been demonstrated in endometrium, decidua, tro-
phoblast and fetal tissue, where TRX may play an important role in
blastocyst implantation and fetal growth (Maruyama et al., 1997;
Kobayashi-Miura et al., 2007).
TRX-binding protein-2 (TBP-2), also known as TRX-interacting
protein or vitamin D3 up-regulated protein, regulates the expression
and function of TRX (Nishiyama et al., 1999; Junn et al., 2000).
Recent studies have elucidated the role of TBP-2 in biologically impor-
tant cellular events. Accumulated evidence suggests that increased
expression of TBP-2 is related to growth suppression and apoptosis
promotion in cells pre-exposed to oxidation through blocking TRX
activity. Indeed, the down-regulation of TBP-2 has been observed in
several human cancers (Kaimul et al., 2007).
These ﬁndings support the hypothesis that TRX and TBP-2 are
involved in the protection of cells against oxidative stresses and the
regulation of cellular proliferation in a number of tissues, and conse-
quently, that dysregulation of TRX and TBP-2 is associated with a
number of disease processes, including those of the reproductive
organs. However, few studies have been reported regarding the
expression and function of TRX and TBP-2 in the human endome-
trium. In addition, there have been no reports about the roles of
TRX and TBP-2 in the development of endometriosis.
This study was conducted to compare the TRX and TBP-2
expression of endometrium between the endometriosis and control
group. We also evaluated the TRX and TBP-2 levels of serum and per-
itoneal ﬂuid in patients with and without endometriosis.
Materials and Methods
Participants
Patients aged 20–45 years who were being managed for benign gynecolo-
gic diseases at the Gangnam Severance Hospital, Seoul, Korea, partici-
pated in this study. All participants had regular menstrual cycles and
none of them had received hormonal treatments, such as GnRH agonists
or oral contraceptives, for at least 3 months prior to surgery. Patients with
diseases closely associated with oxidative stress, such as cancer or cardi-
ovascular disease, or who had taken antioxidants, were excluded. We also
excluded patients with endometrial pathology including endometrial
polyps and endometrial hyperplasia.
Endometrial tissues were obtained by curettage before surgical pro-
cedures and used for real-time polymerase chain reaction (PCR) and
immunohistochemistry (IHC). For those patients, blood and peritoneal
ﬂuid samples were also collected. The diagnosis of endometriosis was con-
ﬁrmed by pathological examination and the clinical stage of the disease was
classiﬁed in accordance with the American Society for Reproductive Medi-
cine (ASRM) revised American Fertility Society (AFS) scoring system. We
diagnosed minimal to mild (Stages I and II) endometriosis in eight patients
and moderate to severe (Stages III and IV) endometriosis in 27 patients.
The control group consisted of 18 patients with benign ovarian cysts, 10
patients with cervical intraepithelial neoplasia, and three patients without
visible pathology in the pelvis. Benign ovarian cysts included simple cysts,
dermoid cysts, serous cystadenoma and mucinous cystadenoma.
The classiﬁcation of endometrium was determined according to the last
menstrual period and histology of endometrium (Noyes et al., 1950) and
divided into six phases of the menstrual cycle (menstrual, early, late pro-
liferative and early-, mid- or late-secretory phase). Thirty-ﬁve women with
endometriosis were from the menstrual (n ¼ 5), early proliferative (n ¼
7), late proliferative (n ¼ 6), early-secretory phase (n ¼ 6), mid-secretory
phase (n ¼ 6) and late-secretory phase (n ¼ 5). Thirty-one control
women were from the menstrual (n ¼ 5), early proliferative (n ¼ 5), late
proliferative (n ¼ 6), early-secretory phase (n ¼ 5), mid-secretory phase
(n ¼ 5) and late-secretory phase (n ¼ 5).
The institutional review board of the Gangnam Severance Hospital
approved this study, and written consent was obtained from all
participants.
RNA extraction and real-time PCR
Total RNA was extracted from endometrial samples using the RNeasy
Mini Kit (Qiagen, Valencia, CA, USA). According to the manufacturer’s
protocols, reverse transcription into cDNA was carried out from 2 mg
of total RNA from each sample using SuperScriptTM III ﬁrst-strand syn-
thesis system (Invitrogen, Carlsbad, CA, USA). TRX and TBP-2 mRNA
levels were measured through a SYBR green real-time PCR using the
ABI PRISM 7300 sequence detection system (Applied Biosystems, Foster
City, CA, USA). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
a housekeeping gene, was used as a normalization control. Speciﬁc
primers for TRX (primer: 50-AGCAGATCGAGAGCAAGACT-30,
reverse primer: 50-CTCTGAAGCAACATCCTGAC-30) and TBP-2
(forward primer: 50-ATAGCGCAGGTACTCCGAAG-30, reverse primer:
50-GGTGAAGTGGAGGTGTGTG-30) were designed. The sequences of
forward and reverse primer for GAPDH were 50-GAAGGTGAAGG
TCGGAGTC-30 and 50-GAAGATGGTGATGGGATTTC-30. Real-time
PCR was performed in a 20-ml buffer including 2 ml of cDNA, 5 pM of
each primer and power SYBR green PCR master mix (Applied Biosys-
tems). The thermal cycling conditions were 508C pre-incubation for
2 min and 958C denaturation for 10 min followed by 40 cycles of 958C
denaturation for 15 s and 608C annealing/extension for 1 min. Relative
TRX and TBP-2 mRNA levels were calculated by the DDCt method as
described previously (Livak and Schmittgen, 2001). The normalization
formula target amount was 22DDCt, where DDCt ¼ [Ct (candidate
gene)2 Ct (GAPDH gene)]2 [Ct (candidate gene calibrator) 2 Ct
(GAPDH gene calibrator)].
Immunohistochemistry
Parafﬁn-embedded sections were deparafﬁnized with xylene, rehydrated in
a graded series of ethanol, and immersed in 3% H2O2 for 10 min to block
endogenous peroxidase activity. Sections were incubated with TRX and
TBP-2 primary antibody (1:200 dilution; Upstate, Lake Placid, NY, USA)
overnight at room temperature and then incubated with a biotin-free poly-
meric horseradish peroxidase-linked antibody conjugate system (LabVi-
sion, Fremont, CA, USA) for 30 min at room temperature. The
chromogen was developed for 2 min. Slides were counterstained with
hematoxylin and mounted in Immunomount for examination. A negative
control was prepared by applying a secondary antibody without a
primary antibody. Representative micrographs of the IHC were photo-
graphed by a Nikon DXM1200F digital camera (Nikon, Japan) at 400
magniﬁcations with 3840  3072 pixel resolution.
The IHC intensity for TRX and TBP-2 was assessed using the following
intensity categories: 0 (no staining), 1þ (weak staining), 2þ (moderate
staining) and 3þ (strong staining). For each slide, a H-score was calculated
as follows: H-score ¼ (% of cells that stained at intensity category 1 
1) þ (% of cells that stained at intensity category 2  2) þ (% of cells
that stained at intensity category 3  3). Slides were scored at different
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times by two investigators blinded to any clinical data. The average score
of the two was used for the ﬁnal analysis.
Measurements of TRX and TBP-2 protein
levels in serum and peritoneal ﬂuid
Blood samples were collected in sterile tubes before surgery and centri-
fuged at 300g for 10 min. Serum samples were obtained and stored at
2808C. Peritoneal ﬂuid samples were aspirated during laparoscopy from
cul-de-sac and obtained from 20 subjects in each group. Peritoneal ﬂuid
samples were also centrifuged at 300g for 10 min and stored at 2808C.
Serum and peritoneal ﬂuid levels of TRX and TBP-2 were determined
by an ELISA using a commercial kit (USCNLIFE, Missouri City, TX,
USA) according to the manufacturer’s protocols. The minimum detectable
concentration was 0.78 ng/ml for TRX and 0.156 ng/ml for TBP-2.
Statistical analysis
Data were expressed as mean+ SD or mean+ SEM where appropriate.
Student’s t-test was used to compare the clinical and laboratory character-
istics of the endometriosis and control groups. The Mann–Whitney U-test
was used to compare the mRNA levels and H-scores of TRX and TBP-2
between the two groups. Serum and peritoneal ﬂuid levels of TRX and
TBP-2 were also compared using the Mann–Whitney U-test. The differ-
ences in the mRNA expression and IHC staining scores of TRX and
TBP-2 through the menstrual cycle were compared using the Kruskal–
Wallis test followed by the Dunn procedure within each group. Pearson’s
correlation coefﬁcient analysis was used for the evaluation of the corre-
lation between the TRX and TBP-2 mRNA levels in the endometrium.
Statistical analyses were performed using Statistical Package for the
Social Sciences (SPSS) 15.0 software (SPSS Inc., Chicago, IL, USA).
P-values of ,0.05 were considered to be statistically signiﬁcant.
Results
TRX and TBP-2 mRNA levels in the
endometrium
TRX mRNA levels were not signiﬁcantly different between individuals
with or without endometriosis. However, the TBP-2 mRNA levels
were signiﬁcantly lower in the endometriosis group, and consequently
the TRX to TBP-2 ratio was signiﬁcantly higher in patients with endo-
metriosis than in the control group (Fig. 1).
There was no variation in TRX and TBP-2 mRNA levels within
either group during the menstrual cycle. TRX mRNA levels were
not signiﬁcantly different between the two groups during the whole
of the menstrual cycle. However, the TBP-2 mRNA levels were signiﬁ-
cantly lower in patients with endometriosis than in the control group
during the menstrual phase. TBP-2 mRNA levels were also consider-
ably lower in patients with endometriosis during the late secretory
phase, although the differences were not statistically signiﬁcant (P ¼
0.076). The TRX to TBP-2 ratio was signiﬁcantly higher in patients
with endometriosis than in the control group during the late-secretory
and menstrual phases (Table I and Fig. 2).
Relationships between TRX and TBP-2
mRNA levels in the endometrium
Pearson’s correlation coefﬁcient was used to investigate the inter-
action between TRX and TBP-2 mRNA levels. TRX mRNA levels
positively correlated with the TBP-2 mRNA levels in the control
group. However, there was no correlation between TRX and TBP-2
mRNA levels in the endometriosis group (Fig. 3).
Immunohistochemistry
The expression of TRX and TBP-2 was observed in endometrial gland-
ular and stromal cells throughout the menstrual cycle (Fig. 4). The
H-scores of TRX were not signiﬁcantly different between the two
groups. However, the H-scores of TBP-2 were signiﬁcantly lower in
patients with endometriosis than in the control group (Fig. 5A).
There was no variation in the H-scores of TRX and TBP-2 in either
group during the menstrual cycle. When the H-scores of TRX and
TBP-2 were compared according to the menstrual cycle within each
group, H-scores of TRX were signiﬁcantly higher than those of
TBP-2 during the late-secretory and menstrual phases in patients
with endometriosis (Fig. 5B and C).
Serum and peritoneal levels of TRX and
TBP-2
TRX and TBP-2 levels in the serum and peritoneal ﬂuid were not sig-
niﬁcantly different between the two groups. In both groups, the TRX
Figure 1 TRX and TBP-2 mRNA levels in the endometrium of
endometriosis and control group (A) and comparison of the TRX
to TBP-2 ratio between the two groups (B). Data are expressed as
mean+ SEM.
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levels were higher than the TBP-2 levels in the serum, but the TRX
levels were not different from the TBP-2 levels in the peritoneal
ﬂuid (Table II).
Discussion
In this study, we have demonstrated a strong correlation between
TRX and TBP-2 mRNA levels in normal endometrium. We have
also demonstrated that altered TRX and TBP-2 expressions in the
endometrium are associated with the development of endometriosis.
Furthermore, we investigated the levels of TRX and TBP-2 in the
serum and peritoneal ﬂuid.
When comparing patients with endometriosis to a control group
regardless of the phase of the menstrual cycle, we did not ﬁnd any
differences in TRX mRNA levels in endometrium. However, we dis-
covered that the levels of TBP-2 mRNA were signiﬁcantly lower
(P, 0.001), and the rate of TRX/TBP-2 was signiﬁcantly higher
(P ¼ 0.003) in patients with endometriosis. In addition, we also
observed decreased TBP-2 immunoreactivity in patients with endo-
metriosis compared with the control group (P, 0.001). On the
other hand, the control group showed a mutually signiﬁcant corre-
lation between the TRX and the TBP-2 mRNA levels in endome-
trium (r ¼ 0.793, P, 0.001), but patients with endometriosis did
not show a signiﬁcant correlation. On the basis of these results,
we may infer that mutual disproportion of TRX and TBP-2 inﬂu-
enced by oxidative stress occurs in patients with endometriosis,
which may be due to decreased expression of TBP-2, a negative reg-
ulator of TRX, rather than increased expression of TRX. Down-
regulation of TBP-2 expression has been reported in numerous
human cancers including prostate cancer, bladder cancer, breast
cancer and colon cancer (Kaimul et al., 2007). Loss of TBP-2 has
also been associated with poor prognosis in patients with B-cell lym-
phoma (Tome et al., 2005). TBP-2 expression up-regulation by
histone deacetylase inhibitors, known to be a speciﬁc class of antic-
ancer agents, simultaneously occurred with a signiﬁcantly decreased
expression of TRX (Butler et al., 2002). Therefore, it seems
that TBP-2 is one of the potent antitumor genes active in growth
regulation and plays a crucial role in the development of
endometriosis.
When we compared the mRNA levels of TRX and TBP-2 based
on the menstrual cycle between the two groups, statistical signiﬁ-
cance was not found in either the proliferative or early-secretory
phases. However, TBP-2 mRNA levels were lower and the rate of
TRX/TBP-2 was higher in the endometriosis group than in the
control group during late-secretory and menstrual phases. Conse-
quently, compared with the control group, patients with endome-
triosis showed relatively higher TRX activity resulting from
down-regulated TBP-2 during the late-secretory and menstrual
phases in comparison with other phases of the menstrual cycle.
Apoptosis fosters cell homeostasis in the human endometrium. It
is believed that the viability of regurgitated endometrial cells is facili-
tated by a decrease in the normal apoptosis process and an increase
in cellular proliferation (Harada et al., 2004). These cells are then
implanted in other sites outside the uterus, which causes endome-
triosis. In patients with endometriosis, it has been reported that
apoptosis is signiﬁcantly decreased in the endometrium during the
late-secretory and menstrual phases, and the endometrium shows
higher proliferation activity, clinically as well as pathologically.
Increased TRX levels are positively correlated with cell proliferation
and negatively correlated with apoptosis in human gastric carcinoma
(Grogan et al., 2000). TRX levels are also increased in several human
cancers such as cervical carcinoma, lung cancer and pancreatic
cancer (Kaimul et al., 2007). Therefore, it may be presumed that
the increased TRX activity in endometrial tissues during the late-
secretory and menstrual phases plays an important role in the devel-
opment of endometriosis through adhesion, inﬁltration and
.............................................................................................................................................................................................
Table I Comparison of the TRX and TBP-2 mRNA levels in the endometrium through the menstrual cycle.
M EP LP ES MS LS P-valuea
TRX
Endometriosis 27.06+7.96 5.65+1.60 10.17+3.63 12.62+2.49 9.47+3.02 17.99+6.89 0.102
Control 6.84+1.72 21.17+8.20 15.34+5.27 30.56+17.88 15.15+2.50 17.59+6.99 0.267
P-valueb 0.076 0.123 0.423 0.465 0.201 0.754
TBP-2
Endometriosis 1.95+0.58 3.33+0.95 4.06+1.20 7.67+1.83 7.79+2.33 3.99+1.26 0.265
Control 9.59+3.77 8.50+2.50 8.34+2.94 30.71+18.43 20.46+12.65 17.31+7.24 0.562
P-valueb 0.016 0.167 0.262 0.361 0.855 0.076
TRX/TBP-2
Endometriosis 18.42+6.87c 1.99+0.46 2.37+0.59 2.05+1.06 1.30+0.18 4.59+1.23c 0.004
Control 0.88+0.17 2.25+0.50 1.90+0.31 1.33+0.36 1.45+0.37 1.07+0.28 0.074
P-valueb 0.008 0.935 0.423 0.201 0.715 0.009
Values are expressed as mean+ SEM. M, menstrual phase; EP, early-proliferative phase; LP, late-proliferative phase; ES, early-secretory phase; MS, mid-secretory phase; LS, late-secretory
phase.
aKruskal–Wallis test was used to analyze the differences of the TRX or TBP-2 mRNA levels in the endometrium through the menstrual cycle within each group.
bMann–Whitney U-test was used to analyze the differences of the TRX and TBP-2 mRNA levels in the endometrium between two groups.
cStatistically signiﬁcant versus MS in Dunn procedure.
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proliferation of endometrial cells regurgitated into the peritoneal
cavity by enhancing endometrial cell growth and suppressing
apoptosis.
Previous reports demonstrated that the expression of TRX
increased during the early-secretory phase of the menstrual cycle
and that it modulates endometrial cell growth, which is regulated by
estrogen and progesterone (Maruyama et al., 1997, 1999). It has
also been reported that, in mice, the TRX knockout is lethal during
the early post-implantation period (Matsui et al., 1996). These
results imply that the expression of TRX in the endometrium is
closely linked to estrogen and progesterone levels and may play an
important role in blastocyst implantation as well as normal embryo
development.
One of the most important ﬁndings of our study was that TRX
mRNA levels were signiﬁcantly correlated with TBP-2 mRNA levels
in the normal endometrium. Consequently, it appears that TBP-2
expression in the endometrium is inﬂuenced by estrogen and that
TBP-2 may inﬂuence implantation of blastocyst and the development
of the embryo. However, in our study, we found no statistically signiﬁ-
cant differences in TRX expression during the menstrual cycle,
although both TRX and TBP-2 expression increased somewhat at
the early-secretory phase compared with the other menstrual
phases. An earlier study using immunostaining also did not demon-
strate a signiﬁcant increase in TRX expression at the early-secretory
phase, while TRX expression at the secretory phase was relatively
higher than at the proliferative phase (Stavreus-Evers et al., 2002).
Several studies have regarded oxidative stress as an important cause
of infertility in endometriosis. These studies found that levels of nitro-
gen oxide and superoxide dismutase change during the menstrual
cycle and are highly expressed at the secretory stage; however,
these changes were not found in patients with endometriosis (Ota
et al., 1999). Other antioxidants, such as xanthine oxidase and cata-
lase, also show abnormal expression in the endometrial tissue of
patients with endometriosis (Ota et al., 2002). The present study
demonstrated that patients with endometriosis had marked alterations
in the expression of TRX and TBP-2 according to the menstrual cycle.
These facts considered, and it may be concluded that antioxidants
show differences in their expression in endometrial tissues according
to the menstrual cycle and that these differences are regulated by
an ovarian steroid hormone. When the balance between the pro-
duction of reactive oxygen species and antioxidant defense system is
Figure 2 TRX and TBP-2 mRNA levels in the endometrium of the
endometriosis (A) and control group (B) and a comparison of
the TRX to TBP-2 ratio between the two groups (C) throughout
the menstrual cycle. M, menstrual phase; EP, early-proliferative
phase; LP, late-proliferative phase; ES, early-secretory phase; MS,
mid-secretory phase; LS, late-secretory phase. Data are expressed
as mean+ SEM.
Figure 3 Pearson’s correlation coefﬁcients between TRX and
TBP-2 mRNA levels in the endometriosis and control group.
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disrupted, the possibility of endometriosis increases and it may thus be
connected to infertility.
The levels of TRX and TBP-2 protein in serum and peritoneal ﬂuid
did not show a difference in either group, and there was no correlation
with the mRNA expression in the endometrium. These results indi-
cate that the changes in TRX and TBP-2 expression in the endome-
trium do not lead to changes in serum and peritoneal ﬂuid levels
and that the levels of TRX and TBP-2 in the serum and peritoneal
ﬂuid have no relation to the development of endometriosis. Our
results corresponded with those of earlier studies that showed that
the levels of TRX in serum had no relation to endometriosis
(Lambrinoudaki et al., 2009). It is presumed that alteration of TRX
and TBP-2 expression in the endometrium may facilitate the inﬂamma-
tory process to induce the development of endometriosis by activating
a transcription factor such as NF-kB, which is associated with the
recruitment of macrophages and the secretion of inﬂammatory cyto-
kines. Moreover, it is known that the serum TRX level is affected by
various conditions, such as rheumatoid arthritis (Yoshida et al.,
1999), type 2 diabetes (Kakisaka et al., 2002) and nonalcoholic fatty
liver disease (Sumida et al., 2003). Accordingly, alteration of TRX
and TBP-2 expression in the endometrium may not be reﬂected in
the serum and peritoneal ﬂuid levels of TRX and TBP-2.
To our knowledge, this report is the ﬁrst to investigate the inﬂu-
ences of oxidative stress on the development of endometriosis by
comparing the mRNA levels of TRX and TBP-2 in the endometrium
of patients with endometriosis to those of a control group. TBP-2
expression and the relationship between TRX and TBP-2 expression
in normal human endometrium were also reported in this study.
This study does have some limitations. We did not have sufﬁcient
participants to compare TRX and TBP-2 levels from individuals with
minimal and mild endometriosis to the levels found in those with mod-
erate and severe endometriosis. Additionally, when subjects were
categorized by the phase of the menstrual cycle, each group included
only 5–7 subjects. Thus, we believe that further studies with larger
sample sizes are necessary.
In conclusion, TRX mRNA levels signiﬁcantly correlated with TBP-2
mRNA levels, a negative regulator of TRX function, in the normal
endometrium. However, TRX and TBP-2 mRNA levels did not corre-
late in women with endometriosis. In particular, TBP-2 mRNA levels
were lower and the TRX to TBP-2 ratio was higher in patients with
Figure 4 Expression of TRX and TBP-2 in the endometrium (400). Representative micrographs of TRX (A) and TBP-2 (B) expression of the
endometriosis group, and TRX (C) and TBP-2 (D) expression of the control group in endometrium throughout the menstrual cycle. (E) Negative
control and the staining intensity of IHC. EP, early-proliferative phase; LP, late-proliferative phase; ES, early-secretory phase; MS, mid-secretory
phase; LS, late-secretory phase; C, negative control.
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endometriosis during the late-secretory and menstrual phases. These
results suggest that TRX and TBP play a crucial role in the homeostasis
of the normal endometrium and that altered TRX and TBP-2
expression in the endometrium is associated with the establishment
of endometriosis. Therefore, TRX and its negative regulator may rep-
resent important future targets to develop clinical therapies for
endometriosis.
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